Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 701–800 of 1,000
Tan, S., Zhang, W., Ding, Y., Liu, J., Zhu, M., Luo, X., Cai, J., & Zeng, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772701 · Cited by 11
Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Fathi, E., Farahzadi, R., Montazersaheb, S., & Bagheri, Y. (2020) · Current Gene Therapy · doi:10.2174/1566523220999201111194554 · Cited by 11
Safaralizadeh, R., Eslahi, M., Nematbakhsh, N., Dastmalchi, N., & Teimourian, S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220119104649 · Cited by 9
Harper, M. M., Lin, M., Qasem, S. A., Patel, R. A., Cavnar, M. J., Pandalai, P. K., Gao, M., & Kim, J. (2022) · Cancers · doi:10.3390/cancers14133051 · Cited by 10
“Since anti-HDAC therapies are nonselective and target epigenetic alterations [17] and anti-EGFR therapies such as erlotinib have failed to show clinically meaningful benefit in PDAC [18,19], we chose to investigate MET, which is a promising therapeutic target for various cancers and is overexpressed, upregulated, and…”
BackgroundRecent advances in HDAC-targeted imaging probes for cancer detection
Tang, C. C., Wang, X., Jin, Y., & Wang, F. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188788 · Cited by 9
Gu, Z., Chen, X., Zhu, D., Wu, S., & Yu, C. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24699 · Cited by 14
Schrenk, C., Bollmann, L. M., Haist, C., Bister, A., Wiek, C., Wecker, M., Roth, D., Petzsch, P., Köhrer, K., Hamacher, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065553 · Cited by 9
Indole and indoline scaffolds in drug discovery
Liu, F., & Su, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00022-x · Cited by 11
Exploring epigenetic strategies for the treatment of osteoporosis
Yi, S.-J., Lim, J., & Kim, K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09353-4 · Cited by 9
“Valproic acid (VPA), a short-chain branched fatty acid primarily prescribed for epilepsy and bipolar disorder management as well as migraine prevention, has exhibited osteogenic potential [76].”
Zhang, Z., Su, R., Liu, J., Chen, K.-Y., Wu, C.-J., Sun, P., & Sun, T.-M. (2024) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2024.117022 · Cited by 9
Iannelli, F., Lombardi, R., Costantini, S., Roca, M. S., Addi, L., Bruzzese, F., Gennaro, E. D., Budillon, A., & Pucci, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03573-1 · Cited by 10
Ali, D., Chalisserry, E. P., Manikandan, M., Hamam, R., Alfayez, M. A., Kassem, M. S., Aldahmash, A. M., & Alajez, N. M. (2018) · Stem Cells International · doi:10.1155/2018/2379546 · Cited by 12
“In the current study, we investigated romidepsin, an HDAC1 and HDAC2 inhibitor, that has been used as an anticancer drug and is known to induce cancer cell cycle arrest, cancer cell differentiation, and cell death [18].”
BackgroundAntonelli, R., Jiménez, C., Riley, M. M., Servidei, T., Riccardi, R., Soriano, A., Roma, J. M., Martínez-Sáez, E. A., Martini, M., Ruggiero, A., et al. (2020) · Cancers · doi:10.3390/cancers12071922 · Cited by 9
“To date, many HDAC inhibitors (HDACis) have been tested in oncology clinical trials, which led to the approval of Vorinostat, Romidepsin, Bellinostat, and Panobinostat for the treatment of cutaneous and peripheral T-cell lymphoma and multiple myeloma [12].”
BackgroundHan, X., Du, J., Zheng, Y.-D., Dai, J., Lin, S.-W., Zhang, B., Zhong, F., Lin, Z.-G., Jiang, S., Wei, W., et al. (2021) · BioMed Research International · doi:10.1155/2021/5089371 · Cited by 9
“The results of most clinical trials were in favor of using HDAC inhibitors either before the initiation of chemotherapy or in combination with other treatments [8].”
ResultRecent Advances in Nanomedicine-Based Delivery of Histone Deacetylase Inhibitors for Cancer Therapy
Hafez, D. A., Hassanin, I. A., Teleb, M., Khattab, S. N., Elkhodairy, K. A., & Elzoghby, A. O. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0196 · Cited by 10
Behnisch‐Cornwell, S., Grathwol, C. W., Schulig, L., Voigt, A., Baecker, D., Link, A., & Bednarski, P. J. (2021) · Cancers · doi:10.3390/cancers14010187 · Cited by 9
“In recent years, the HDAC inhibitors vorinostat, panabinostat, belinostat, and romidepsin have been approved as drugs for the treatment of haematological malignancies, as well as various solid tumors [6,7].”
Chemotherapy-Induced Arrhythmias
Essa, H., Dobson, R., & Lip, G. Y. H. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001216 · Cited by 10
“7 Histone deacetylase inhibitors The Histone deacetylase inhibitors inhibit the prol iferation of tumour cells by inducing cell cycle arrest and apoptosis [69].”
BackgroundOmidkhah, N., Eisvand, F., Hadizadeh, F., Zarghi, A., & Ghodsi, R. (2022) · ChemistrySelect · doi:10.1002/slct.202201239 · Cited by 10
Transformation of follicular lymphoma – Why does it happen and can it be prevented?
Link, B. K. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.10.005 · Cited by 9
HDAC3 inhibition disrupts the assembly of meiotic apparatus during porcine oocyte maturation
Gu, L., Li, X., Liu, X., Gao, M., He, Y., Xiong, B., & Liu, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27687 · Cited by 9
Dually Efficacious Medicine Against Fibrosis and Cancer
Chen, D. (2019) · Medical Sciences · doi:10.3390/medsci7030041 · Cited by 10
“In this light, several HDAC inhibitors including vorinostat, romidepsin and chidamide have been developed and approved for T-cell lymphoma, followed by panobinostat for multiple myeloma [44,45].”
BackgroundKey actors in cancer therapy: epigenetic modifiers
Akar, R. O., Selvi, S., Ulukaya, E., & Aztopal, N. (2019) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1903-39 · Cited by 9
“The 5 currently FDA-approved HDAC inhibitors are vorinostat (SAHA) for cutaneous T-cell lymphoma, romidepsin for cutaneous/peripheral T-cell lymphoma, belinostat for peripheral T-cell lymphoma, panobinostat for multiple myeloma, and valproic acid (VPA) for epilepsy, bipolar disorder, and migraine (Eckschlager et al.,…”
BackgroundEpigenetic alterations of testicular germ cell tumours
Ilijazi, D., Shariat, S., Hassler, M. R., Lemberger, U. J., & Ertl, I. E. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000724 · Cited by 9
“Several HDAC inhibitors are at present in clinical studies or have already been approved for various cancer types [46].”
BackgroundDu, C., Zhu, Y., Duan, J., Yang, Y., Ren, Y., Mu, L., Yan, Z., Li, G., Wang, H., Shi, Y., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118217 · Cited by 10
Ashwini, K., Acharya, R., Roopashree, P. G., Raghotham, A., Baud, S., Rao, R., & Kumari, S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152216 · Cited by 8
Ledesma, S. N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207315 · Cited by 11
“…crosstalk, where glucocorticoid receptor activation suppresses ER-mediated transcription [145]; (ii) Histone deacetylase activation, which closes chromatin at ER target sites [146]; (iii) Direct inhibition of aromatase, reducing local estrogen synthesis in tissues such as fat and muscle [147].”
Truong, N., Goodis, C. C., Cottingham, A. L., Shaw, J. R., Fletcher, S., & Pearson, R. M. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00119 · Cited by 8
Shetty, M. G., Pai, P., Padavu, M., Satyamoorthy, K., & Babitha, K. S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116324 · Cited by 9
Ghosh, R., & Chattopadhyay, S. K. (2024) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202400228 · Cited by 8
TSA attenuates the progression of c-Myc-driven hepatocarcinogenesis by pAKT-ADH4 pathway
Liu, Y., Yu, J., An, X., Rao, H., Qiu, Z., Ke, J., Wu, L., Zhu, Z., Deng, H., Wu, F., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12781-x · Cited by 8
“Importantly, the process of deacetylation can be reversed by new targeting drugs, such as HDAC inhibitors (HDACi) [5, 26].”
BackgroundRecent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme
Vatankhah, A., Moghaddam, S. H., Afshari, S., Afshari, A. R., Kesharwani, P., & Sahebkar, A. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155636 · Cited by 9
Song, Y., Ren, S., Wu, S.-M., Liu, W., Hu, C., Feng, S., Chen, X., Tu, R., & Gao, F. (2024) · International Journal of Cancer · doi:10.1002/ijc.35285 · Cited by 9
“37 Of particular interest, belinostat, an HDAC inhibitor approved by the United States FDA for the treatment of relapsed and refractory peripheral T-cell lymphoma, 37,38 was selected for further evaluation regarding its potential to reverse the invasion caused by GC. SONG ET AL .”
Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma
Mehra, N., Sundaram, S., Shah, P. S., & Rao, A. K. D. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01623-5 · Cited by 11
“The study also listed HDAC inhibitors like vorinostat and valproic acid, which are potential agents that could decrease the migration ability of myeloma cells [66, 67].”
Histone deacetylase in inflammatory bowel disease: novel insights
Li, C., Gu, S., Zhang, Y., Zhang, Z., Wang, J., Gao, T., Zhong, K., Shan, K., Ye, G., Ke, Y., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251318833 · Cited by 13
The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
Kalemoglu, E., Jani, Y. C., Canaslan, K., & Bilen, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1506278 · Cited by 9
“This promotes tumor suppressor activity and boosts immune responses by upregulating MHC I and II, signi fi cantly improving the ef fi cacy of IO (107 – 109).”
Aboukhatwa, S. M., Hanigan, T. W., Taha, T. Y., Jayaprakash, N., Ranjan, R., El-Bastawissy, E. A., Elkersh, M. A., El-Moselhy, T. F., Frasor, J. M., Mahmud, N., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900114 · Cited by 8
Колотаев, А. В., Matevosyan, K. R., Осипов, В. Н., & Khachatryan, D. S. (2019) · Tetrahedron Letters · doi:10.1016/j.tetlet.2019.151315 · Cited by 8
Babu, G., Chaudhuri, P., Rajappa, M., Biswas, M., Sansar, B., Rajegowda, C., Radhakrishnan, A., Advani, J., Tewary, B., Radhakrishnan, P., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1831371 · Cited by 9
Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein–Taybi Syndrome
Fede, E. D., Ottaviano, E., Grazioli, P., Ceccarani, C., Galeone, A., Parodi, C., Colombo, E. A., Bassanini, G., Fazio, G., Severgnini, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073621 · Cited by 11
“Considering HDACi applications as anticancer drugs for their role in cell cycle arrest, cell death, and immune-mediated mechanisms [25], we studied NaB and other HDACi effects on cell proliferation and apoptosis, performing Ki67 and Tunel assays upon exposure of LCLs with HDACi (Figures S2 and S3).”
BackgroundSanaei, M., & Kavoosi, F. (2021) · PubMed Central · doi:10.22037/ijpr.2021.115105.15197 · Cited by 16
Xu, X. J., Zhang, D., Zhao, T., Wang, M., Li, Y., Du, Q., Kou, J., Li, Z., & Bian, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114228 · Cited by 8
Muresanu, C., & Егорович, Х. С. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.1118 · Cited by 11
“…(Kelly et al. , 2010) to enhance the cytotoxic agent efficiency for an increased clinical response, such as histone deacetylase (HDAC) inhibitors (Eckschlager et al. , 2017), which are known since, at least, two decades (Vigushin and Coombes, 2002) and they now may be used in combinational…”
HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling
Vong, P., Messaoudi, K., Jankovsky, N., Gomilla, C., Demont, Y., Caulier, A., Jedraszak, G., Demagny, J., Djordjevic, S., Boyer, T., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17559 · Cited by 8
The role and application of transcriptional repressors in cancer treatment
Park, M., Kang, K. W., & Kim, J. W. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01427-4 · Cited by 9
Shahraki, K., Shahraki, K., Boroumand, P. G., & Sheervalilou, R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2240238 · Cited by 8
“Among the many types of histone modifications, histone acetylation, mediated by histone lysine acetyltransferases (HATs) and histone deacetylases (HDACs), is one of the better-studied mechanisms [151,152].”
BackgroundHolay, N., Somma, A. J., Duchow, M. W., Soleimani, M., Capasso, A., Kottapalli, S., Rios, J., Giri, U. P., Diamond, J. R., Schreiber, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260545 · Cited by 9
“While originally recognized for decreasing gene expression by deacetylating histones, thus leading to a closed chromatin state, altered acetylation states and aberrantly overexpressed HDACs have been found in multiple tumor types, ultimately leading to the use of HDAC inhibitors (HDACi) to treat cancer patients (1).”
BackgroundMéhul, B., Perrin, A., Grisendi, K., Galindo, A. N., Dayon, L., Ménigot, C., Rival, Y., & Voegel, J. J. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.07.003 · Cited by 8
Liu, Z., Jing, Q., Wang, Y., Li, Y., Mi, F., Xiang, C., & Fu, R. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3963 · Cited by 8
“HdAcis bind to the catalytic region of HdAcs, reduce their activity, and exert their antitumor effects by altering epigenetic modifications (8). chidamide is a novel benzamide class of HdAci, which was developed in china.”
Mastoraki, A. T., Schizas, D., Vlachou, P., Melissaridou, N., Charalampakis, N., Fioretzaki, R., Kole, C., Savvidou, O. D., Vassiliu, P., & Pikoulis, E. A. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00487-2 · Cited by 9
Targeting transcription factors in cancer drug discovery
Mitra, P. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00025 · Cited by 9
“HDAC inhibitor vorinostat, romidepsin, and panobinostat are currently approved for the treatment of T-Cell lymphoma and multiple myeloma [6].”
BackgroundMahady, G. B., Kanabar, P. N., Los, N. S., Lawal, T. O., Patel, S., Maienschein‐Cline, M., & Arbieva, Z. H. (2021) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v11i4.784 · Cited by 8
“HDACs are involved in the epigenetic regulation of gene expression via histone modification and chromatin remodeling, and are categorized into class I (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 6, 7, 9 and 10), class III (Sirutins 1-7) and class IV (HDAC11) [83-85].”
BackgroundZalloum, W. A., & Zalloum, N. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c01696 · Cited by 9
Han, C., Yu, X., Zhang, C., Cai, Y., Cao, Y., Wang, S., & Shen, J. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190916120128 · Cited by 8
Menezes, A., Julião, G., Mariath, F., Ferreira, A. L., Oliveira-Nunes, M. C., Gallucci, L., Evaristo, J. A. M., Nogueira, F. C. S., Pereira, D. D. A., & Carneiro, K. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100722 · Cited by 8
“Although the use of iHDACs for oncology has been approved only for T-cell lymphoma or for multiple myeloma, new iHDACs are being developed for clinical use, which highlights their potential for cancer treatment (44 – 46).”
BackgroundStructural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer
Chen, Y., Su, J., Li, S., Chen, F., Zhang, Y., Wang, X., Zhang, Y., Wang, X., Yuan, Z., Ren, S., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673332285241104091609 · Cited by 8
Chatterjee, E., Sharma, R., Dey, B., Singh, H., Naik, A., Khan, A., Basak, S., Bansode, A., Sachdeva, R., Sharma, A., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544666 · Cited by 10
“In contemporary studies, histone deacetylase inhibitors (HDACis) are among the most widely studied compounds because of their anticancer activities (Eckschlager et al., 2017; Li and Seto, 2016).”
Kawata, K., Chapman, O. S., Narumi, S., & Kawauchi, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1569548 · Cited by 8
Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression
Puviindran, B. J., Wallace, S., Ayasoufi, K., Lerner, E., & Fecci, P. E. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf006 · Cited by 15
“139,140 Therapies targeting myeloid cells to date have most typically aimed at impacting macrophage polarization.”
CREPT Disarms the Inhibitory Activity of HDAC1 on Oncogene Expression to Promote Tumorigenesis
Cao, Y., Ning, B., Tian, Y., Lan, T., Chu, Y., Ren, F., Wang, Y., Meng, Q., Li, J., Jia, B., et al. (2022) · Cancers · doi:10.3390/cancers14194797 · Cited by 8
Xing, L., Gong, G., Chen, X., & Chen, X. (2023) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00635 · Cited by 7
Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease
Ding, H., Li, Y., Fang, M., Chen, J., Liu, L., Lu, Z., Hou, J., & Luo, M. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.04.003 · Cited by 7
Gabano, E., Gariboldi, M. B., Marras, E., Barbato, F., & Ravera, M. (2023) · Dalton Transactions · doi:10.1039/d3dt01876h · Cited by 7
Nakatake, M., Kurosaki, H., & Nakamura, T. (2023) · Cancer Science · doi:10.1111/cas.16032 · Cited by 8
Mariotto, E., Canton, M., Marchioro, C., Brancale, A., Hamel, E., Varani, K., Vincenzi, F., Ventura, T. D., Padroni, C., Viola, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147519 · Cited by 7
“Inhibition of HDACs is therefore regarded as an important target for cancer therapy [36].”
Wang, J., Wu, W., Wan, J., Zhan, L., Chen, Y., Yun, F., Ji, Y., Suo, G., Zheng, Y., Shen, D., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116449 · Cited by 9
Yang, L., Sui, H., Ding, Y., Zhu, Y., Song, X., Zhang, Y., Fan, G., Wang, J., Cui, X., Jiang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217419 · Cited by 12
Chemical catalyst manipulating cancer epigenome and transcription
Yamanashi, Y., Takamaru, S., Okabe, A., Kaito, S., Azumaya, Y., Kamimura, Y. R., Yamatsugu, K., Kujirai, T., Kurumizaka, H., Iwama, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56204-2 · Cited by 8
A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
Ghanbari, M., Safaralizadeh, R., & Mohammadi, K. (2018) · Current Cancer Therapy Reviews · doi:10.2174/1573394714666180720152100 · Cited by 8
Gürboğa, M., Kugu, G., Kamberaj, H., & Mutlu, Ö. (2021) · Parasitology Research · doi:10.1007/s00436-021-07158-z · Cited by 8
“Since it is known that inhibition of HDACwill disrupt the HAT/HDAC balance, HDACs are seen as important drug targets (Minucci et al. 2001; Hull et al. 2016; Eckschlager et al. 2017).”
BackgroundSang, W., Xu, K., Xu, L., Qin, Y., Liu, M., Jiao, J., Tu, D., Zhang, M., Yan, D., Song, X., et al. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210908103306 · Cited by 7
Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
Li, X., Yuan, X., Wang, Z., Li, J., Liu, Z., Wang, Y., Wei, L., Li, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819714 · Cited by 8
Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach
Perumal, E., Ezhilarasan, D., & Thangavelu, L. P. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105801 · Cited by 7
Martewicz, S., Zhu, X., Qu, S., Cui, M., Grespan, E., Luni, C., Jiang, B., Yang, G., & Elvassore, N. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121564 · Cited by 8
Gao, C., Zhang, L., Xu, Y. F., Ma, X., Chen, P., Chen, Z., & Wei, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1183052 · Cited by 8
“HDAC inhibitors (HDACi) are novel drugs for tumor-targeted therapy that inhibit tumor cell proliferation and induce cell differentiation or apoptosis by increasing the acetylation level of intracellular histones (Manal et al., 2016; Eckschlager et al., 2017).”
BackgroundTiwari, S., Liu, S., Anees, M., Mehrotra, N., Thakur, A., Tawa, G. J., Grewal, G. S., Stone, R. M., Kharbanda, S. M., & Singh, H. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10541 · Cited by 7
“For example, cisplatin combined with doxorubicin or paclitaxel is given to treat patients with inherited BRCA (BReast CAncer) gene mutations.2,3 The combination of bromodomain and extraterminal motif (BET) inhibitor with PI3-K inhibitor showed promising anticancer effects in metastatic breast cancer.4 Phosphoinositide…”
BackgroundJankowski, K., Jagana, V., Bisserier, M., & Hadri, L. (2023) · Biomedicines · doi:10.3390/biomedicines12010010 · Cited by 7
Cogo, F., Poręba, M., Rut, W., Groborz, K. M., Smyth, P., Johnston, M. C., Williams, R. D., Longley, D. B., Burden, R. E., Salvesen, G. S., et al. (2018) · Nanoscale · doi:10.1039/c8nr07859a · Cited by 7
Miles, M. A., Harris, M. A., & Hawkins, C. J. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01543-x · Cited by 7
“This can lead to a multitude of cell signalling events such as apoptosis, cell differentiation or cell cycle arrest [10].”
BackgroundTranslational Research in Cancer
Sundaresan, S., & Gu, Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73772 · Cited by 8
Benincasa, G., Vasco, M., Corrado, A., Sansone, A., Picascia, A., & Claudio Napoli, A. (2021) · Clinical Transplantation · doi:10.1111/ctr.14306 · Cited by 7
Zhao, M., Duan, Y., Wang, J., Liu, Y., Zhao, Y., Wang, H., Zhang, L., Chen, Z., Hu, Z., & Wei, L. (2022) · Journal of Oncology · doi:10.1155/2022/3345536 · Cited by 7
“Decades of research has shown that the inhibition of HDACs leads to cell cycle arrest, cell differentiation, or cell apoptosis, and decreases cell proliferation by altering the acetylation status of histone or non-histone proteins [13, 14].”
BackgroundDual Targeting Autoimmunity and Cancer: From Biology to Medicine
Chen, D. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1100 · Cited by 7
Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review
Debbarma, M., Sarkar, K., & Sil, S. K. (2024) · Medical Oncology · doi:10.1007/s12032-024-02553-9 · Cited by 9
“Class I consists of HDAC1, HDAC2, HDAC3, and HDAC8 [32].”
Sekeres, M., Lengle, D., Abbey, L., Kassack, M. U., Fischer, F., Kurz, T., & Fritz, G. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120018 · Cited by 6
Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies
Kaszycki, J., & Kim, M. (2025) · Biology · doi:10.3390/biology14070838 · Cited by 8
“Sirtuin inhibitors such as nicotinamide and EX-527 modulate NAD+-dependent HDACs and are under investigation for cancer [102].”
Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors
Yuan, Y., Wang, C., Duan, J., Zhang, P., He, M.-L., Liu, Z., Hui, Z., & Ye, X. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11282-8 · Cited by 6
“These HDACs inhibitors (HDACi) have shown good anti-tumor effects but are often limited by narrow anti-tumor spectra (often hematology tumors rather than solid tumors), drug resistance, and adverse effects [40–43].”
Dutta, S., Ghosh, S., Mishra, A. B., & Ghosh, R. (2022) · Journal of Proteins and Proteomics · doi:10.1007/s42485-022-00100-6 · Cited by 7
Guo, X., Zhao, X., Li, L., Jiang, M., Zhou, A., Gao, Y., Zheng, P., Liu, J., & Zhao, X. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106592 · Cited by 6
Hemithioindigo-based histone deacetylase inhibitors induce a light-dependent anticancer effect
Josa‐Culleré, L., Rodríguez, C. A., & Llebaria, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116846 · Cited by 6
Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas
Fischer, A., Albert, T., Moreno, N., Interlandi, M., Mormann, J., Glaser, S., Patil, P., de Faria, F. W., Richter, M., Verma, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52826-0 · Cited by 9
Madrigal-Angulo, J. L., Hernández‐Fuentes, G. A., Parra‐Delgado, H., Valdez, M. O., Martínez, I. I. P., Cabrera‐Licona, A., Espinosa‐Gil, A., Delgado‐Enciso, I., & Martínez‑Martínez, F. (2024) · Biomedical Reports · doi:10.3892/br.2024.1884 · Cited by 7
“Histone deacetylase (HDAC) inhibitors are a promising new class of anticancer drugs, which indirectly modifies the expression of genes (4).”
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Shirbhate, E., Singh, V. P., Kore, R., Koch, B., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2458156 · Cited by 8
“Several first-generation, traditional HDACi, especially for cancer treatment, have received approval as therapeutic agent or are currently being developed and facing clinical exposure [9–11].”
Cell morphology and gene expression: tracking changes and complementarity across time and cell lines
Lejal, V., Rouquié, D., & Taboureau, O. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117530 · Cited by 10
Lysine Acetylation of Proteins and Its Characterization in Human Systems
Orren, D. K., & Machwe, A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9434-2_7 · Cited by 6
Ohmuro‐Matsuyama, Y., Kitaguchi, T., Kimurâ, H., & Ueda, H. (2021) · ACS Omega · doi:10.1021/acsomega.0c06281 · Cited by 6
Kim, H. Y., Choi, S. A., Koh, E. J., Kim, K. H., Phi, J. H., Lee, J. Y., & Kim, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648023 · Cited by 6
“HDAC1, which is a Class I HDAC, has been reported to play important roles in epigenetic regulation for tumor progression and is significantly overexpressed in many cancers (10, 12), including AT/RT (13, 14).”
BackgroundSulistyowati, I., Sukpaita, T., Limjeerajarus, C. N., & Ampornaramveth, R. S. (2021) · Frontiers in Dental Medicine · doi:10.3389/fdmed.2021.765462 · Cited by 6
“Currently, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA or Vorinostat), hydroxamate acid HDAC inhibitors (HDACis) (20, 23, 25), are the most studied HDACis in the field of odontogenic-induction; however, only SAHA is approved by the United States Food and Drug Administration (FDA) for clinical use in…”
BackgroundLee, J., Cho, M. C., Son, H., & Kim, S. W. (2022) · Andrology · doi:10.1111/andr.13154 · Cited by 6
Krishnan, M., Saraswathy, S., Singh, S., Saggu, G. K., Kalra, N., Agrawala, P. K., Abraham, K. M., & Toora, B. D. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.03.005 · Cited by 6
Tang, Z., Liu, L., & Borlak, J. T. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01500-1 · Cited by 10
“The use of epigenetic drugs with other drugs such as etoposide, doxorubicin and bortezomib improves therapeutic potency in assays with various cancer cell lines [26], and Belinky et al.”
Background
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
